## Martha Sedegah

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/662873/publications.pdf

Version: 2024-02-01

45 papers

1,079 citations

471509 17 h-index 32 g-index

46 all docs

46 docs citations

46 times ranked

1264 citing authors

#	Article	IF	CITATIONS
1	Towards large-scale identification of HLA-restricted T cell epitopes from four vaccine candidate antigens in a malaria endemic community in Ghana. Vaccine, 2022, 40, 757-764.	3.8	3
2	CHARM: COVID-19 Health Action Response for Marines–Association of antigen-specific interferon-gamma and IL2 responses with asymptomatic and symptomatic infections after a positive qPCR SARS-CoV-2 test. PLoS ONE, 2022, 17, e0266691.	2.5	1
3	Messenger RNA expressing PfCSP induces functional, protective immune responses against malaria in mice. Npj Vaccines, 2021, 6, 84.	6.0	52
4	IMRASâ€"Immunization with radiation-attenuated Plasmodium falciparum sporozoites by mosquito bite: Cellular immunity to sporozoites, CSP, AMA1, TRAP and CelTOS. PLoS ONE, 2021, 16, e0256396.	2.5	6
5	A three-antigen Plasmodium falciparum DNA prime—Adenovirus boost malaria vaccine regimen is superior to a two-antigen regimen and protects against controlled human malaria infection in healthy malaria-naÃ⁻ve adults. PLoS ONE, 2021, 16, e0256980.	2.5	10
6	Comparison of the impact of allelic polymorphisms in PfAMA1 on the induction of T Cell responses in high and low malaria endemic communities in Ghana. Malaria Journal, 2021, 20, 367.	2.3	2
7	Comparative analysis of the ex vivo IFN-gamma responses to CD8+ T cell epitopes within allelic forms of PfAMA1 in subjects with natural exposure to malaria. PLoS ONE, 2021, 16, e0257219.	2.5	3
8	An open label study of the safety and efficacy of a single dose of weekly chloroquine and azithromycin administered for malaria prophylaxis in healthy adults challenged with 7G8 chloroquine-resistant Plasmodium falciparum in a controlled human malaria infection model. Malaria Journal, 2020, 19, 336.	2.3	1
9	IMRASâ€"A clinical trial of mosquito-bite immunization with live, radiation-attenuated P. falciparum sporozoites: Impact of immunization parameters on protective efficacy and generation of a repository of immunologic reagents. PLoS ONE, 2020, 15, e0233840.	2.5	20
10	A Phase IIa Controlled Human Malaria Infection and Immunogenicity Study of RTS,S/AS01E and RTS,S/AS01B Delayed Fractional Dose Regimens in Malaria-Naive Adults. Journal of Infectious Diseases, 2020, 222, 1681-1691.	4.0	29
11	Novel malaria antigen Plasmodium yoelii E140 induces antibody-mediated sterile protection in mice against malaria challenge. PLoS ONE, 2020, 15, e0232234.	2.5	2
12	Identification of Plasmodium falciparum circumsporozoite protein-specific CD8+ T cell epitopes in a malaria exposed population. PLoS ONE, 2020, 15, e0228177.	2.5	4
13	Title is missing!. , 2020, 15, e0228177.		0
14	Title is missing!. , 2020, 15, e0228177.		0
15	Title is missing!. , 2020, 15, e0228177.		0
16	Title is missing!. , 2020, 15, e0228177.		0
17	Antibody-Dependent, Gamma Interferon-Independent Sterilizing Immunity Induced by a Subunit Malaria Vaccine. Infection and Immunity, 2019, 87, .	2.2	6
18	Antigenicity and immune correlate assessment of seven Plasmodium falciparum antigens in a longitudinal infant cohort from northern Ghana. Scientific Reports, 2019, 9, 8621.	3.3	2

#	Article	IF	CITATIONS
19	T-cell responses against Malaria: Effect of parasite antigen diversity and relevance for vaccine development. Vaccine, 2018, 36, 2237-2242.	3.8	37
20	Development of whole sporozoite malaria vaccines. Expert Review of Vaccines, 2017, 16, 45-54.	4.4	32
21	Cellular immune response to DNA and vaccinia prime-boost immunization kills Plasmodium yoelii-infected hepatocytes in vitro. Pathogens and Disease, 2017, 75, .	2.0	1
22	Development of replication-deficient adenovirus malaria vaccines. Expert Review of Vaccines, 2017, 16, 261-271.	4.4	14
23	New gorilla adenovirus vaccine vectors induce potent immune responses and protection in a mouse malaria model. Malaria Journal, 2017, 16, 263.	2.3	13
24	Protection against Plasmodium falciparum malaria by PfSPZ Vaccine. JCI Insight, 2017, 2, e89154.	5.0	195
25	Mosquito bite immunization with radiation-attenuated Plasmodium falciparum sporozoites: safety, tolerability, protective efficacy and humoral immunogenicity. Malaria Journal, 2016, 15, 377.	2.3	29
26	Vaccine Strain-Specificity of Protective HLA-Restricted Class 1 P. falciparum Epitopes. PLoS ONE, 2016, 11, e0163026.	2.5	14
27	Seroprevalence of Antibodies against Plasmodium falciparum Sporozoite Antigens as Predictive Disease Transmission Markers in an Area of Ghana with Seasonal Malaria Transmission. PLoS ONE, 2016, 11, e0167175.	2.5	14
28	Decrease in circulating CD25 hi Foxp3 + regulatory T cells following vaccination with the candidate malaria vaccine RTS,S. Vaccine, 2016, 34, 4618-4625.	3.8	2
29	Measurement of ex vivo ELISpot interferon-gamma recall responses to Plasmodium falciparum AMA1 and CSP in Ghanaian adults with natural exposure to malaria. Malaria Journal, 2016, 15, 55.	2.3	12
30	Ad35.CS.01 - RTS,S/AS01 Heterologous Prime Boost Vaccine Efficacy against Sporozoite Challenge in Healthy Malaria-Naà ve Adults. PLoS ONE, 2015, 10, e0131571.	2.5	97
31	Discovery of Novel Plasmodium falciparum Pre-Erythrocytic Antigens for Vaccine Development. PLoS ONE, 2015, 10, e0136109.	2.5	36
32	Controlled Human Malaria Infection (CHMI) differentially affects cell-mediated and antibody responses to CSP and AMA1 induced by adenovirus vaccines with and without DNA-priming. Human Vaccines and Immunotherapeutics, 2015, 11, 2705-2715.	3.3	4
33	The Ex Vivo IFN- $\hat{l}^3$ Enzyme-Linked Immunospot (ELISpot) Assay. Methods in Molecular Biology, 2015, 1325, 197-205.	0.9	9
34	Co-expression of Interleukin-15 Enhances the Protective Immune Responses Induced by Immunization with a Murine Malaria MVA-Based Vaccine Encoding the Circumsporozoite Protein. PLoS ONE, 2015, 10, e0141141.	2.5	1
35	Sterile Immunity to Malaria after DNA Prime/Adenovirus Boost Immunization Is Associated with Effector Memory CD8+T Cells Targeting AMA1 Class I Epitopes. PLoS ONE, 2014, 9, e106241.	2.5	58
36	Identification of minimal human MHC-restricted CD8+ T-cell epitopes within the Plasmodium falciparum circumsporozoite protein (CSP). Malaria Journal, 2013, 12, 185.	2.3	30

3

#	Article	IF	CITATIONS
37	Ex vivo tetramer staining and cell surface phenotyping for early activation markers CD38 and HLA-DR to enumerate and characterize malaria antigen-specific CD8+ T-cells induced in human volunteers immunized with a Plasmodium falciparum adenovirus-vectored malaria vaccine expressing AMA1. Malaria Journal, 2013, 12, 376.	2.3	18
38	Human adenovirus 5-vectoredPlasmodium falciparumNMRC-M3V-Ad-PfCA vaccine encoding CSP and AMA1 is safe, well-tolerated and immunogenic but does not protect against controlled human malaria infection. Human Vaccines and Immunotherapeutics, 2013, 9, 2165-2177.	3.3	30
39	DNA Prime/Adenovirus Boost Malaria Vaccine Encoding P. falciparum CSP and AMA1 Induces Sterile Protection Associated with Cell-Mediated Immunity. PLoS ONE, 2013, 8, e55571.	2.5	127
40	Adenovirus 5-Vectored P. falciparum Vaccine Expressing CSP and AMA1. Part A: Safety and Immunogenicity in Seronegative Adults. PLoS ONE, 2011, 6, e24586.	2.5	63
41	Vaxfectin® enhances both antibody and in vitro T cell responses to each component of a 5-gene Plasmodium falciparum plasmid DNÁ vaccine mixture administered at low doses. Vaccine, 2010, 28, 3055-3065.	3.8	14
42	Vaxfectinâ,,¢ enhances immunogenicity and protective efficacy of P. yoelii circumsporozoite DNA vaccines. Vaccine, 2006, 24, 1921-1927.	3.8	20
43	Immunological Responses of Neonates and Infants to DNA Vaccines. , 2006, 127, 239-252.		4
44	Successful Induction of CD8 T Cell-Dependent Protection Against Malaria by Sequential Immunization with DNA and Recombinant Poxvirus of Neonatal Mice Born to Immune Mothers. Journal of Immunology, 2003, 171, 3148-3153.	0.8	26
45	Persistence of Protective Immunity to Malaria Induced by DNA Priming and Poxvirus Boosting: Characterization of Effector and Memory CD8+-T-Cell Populations. Infection and Immunity, 2002, 70, 3493-3499.	2.2	38